Contents
On this page
- The ICMJE and the purpose of its Recommendations
- Origins of the document and a discrepancy in its dating
- The four authorship criteria and the requirements of each
- A non-compliant author list and its correction
- Contributors who are not authors, and group authorship
- Registration, ethics approval and data sharing requirements and their effective dates
- The six conditions for acceptable secondary publication
- Where the ICMJE and GPP differ in scope
- Limitations of the ICMJE Recommendations
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Publication · ICMJE Recommendations
The ICMJE Recommendations: Scope, Requirements and Limitations of the Instrument
The ICMJE Recommendations are a journal-facing instrument. They determine what a journal may accept, who may be listed as an author, and what must be registered and declared at submission. They say almost nothing about how a research programme should be planned, which is the gap filled by Good Publication Practice; both instruments are therefore required.
Most researchers encounter the ICMJE through a form: a contributorship grid, a disclosure page, or a field requesting a registration number. This is the instrument operating as designed. The Recommendations are addressed to editors and to those who submit to them, and they are enforced at the point of submission. An understanding of what they contain, and of what they omit, indicates which questions they resolve and which must be resolved elsewhere.
Learning objectives
- The nature of the ICMJE: a small committee rather than a membership or certifying body
- The four authorship criteria in their current form, what each one means in practice, and why all four must be met
- The six conditions under which the ICMJE accepts secondary publication in another language or for a different readership
- The registration, data-sharing and ethics-approval requirements, with the dates from which each applies
- Where the ICMJE Recommendations and GPP overlap, where they diverge, and which one answers a given question
- How to write a contributorship statement that an editor will accept rather than return
Common misconceptions
- “My journal is ICMJE-accredited.” No such accreditation exists. A journal may state that it follows the Recommendations; the ICMJE itself is a small group of editors and does not accredit, certify or audit any journal.
- “Three of the four authorship criteria is close enough.” Every author must meet every criterion. A contributor who satisfies three belongs in the acknowledgements, irrespective of seniority.
- “Funding the study, or supplying the material, earns authorship.” The ICMJE excludes acquisition of funding, general supervision and provision of materials as grounds for authorship on their own.
- “ICMJE compliance means my publication practice is covered.” The Recommendations govern a submission. They do not require a written agreement with a sponsor, a publication plan, or that an unwelcome study be written up at all.
- “Registering the trial before I submit is enough.” Registration must be at or before first patient enrolment. Retrospective registration at submission does not satisfy the policy, and the registration date is visible to the editor.
The ICMJE and the purpose of its Recommendations
The International Committee of Medical Journal Editors is a small working group of general medical journal editors, plus the US National Library of Medicine. It is not a society with members, it does not accredit journals, and nothing it publishes has legal force. What it produces is a single document — the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals — which a very large number of journals have chosen to adopt, in whole or in part, as the basis of their own instructions to authors 1.
That adoption is the source of its authority. When a journal says it follows the ICMJE Recommendations, the Recommendations become that journal’s submission conditions, and failure to meet them has immediate consequences: a returned contributorship statement, a request for a registration number that does not exist, a rejection on redundant publication. The document is best read as the common grammar of medical journal submission rather than as an ethical code in the abstract.
The practical consequence is that the Recommendations are organised around the moment of submission. They are detailed on who may be named, what must be declared and what a journal may publish, but nearly silent on what happens in the eighteen months before a manuscript exists.
Origins of the document and a discrepancy in its dating
The document originated as the Uniform Requirements for Manuscripts Submitted to Biomedical Journals — the URM, a name still used in older SOPs and training material. It began as a technical harmonisation exercise: a common format that spared authors from re-typesetting a manuscript for every journal. The scope widened steadily, from manuscript preparation to authorship, then to conflicts of interest, trial registration, data sharing and the handling of misconduct. In 2013 the document was renamed the Recommendations, which reflected what it had already become: not a formatting standard with ethics attached, but an ethics and policy document with a formatting annexe 3.
The 2013 revision also added the fourth authorship criterion — agreement to be accountable for all aspects of the work — to the three that had stood before it 1,3. This is the most consequential change in the document’s recent history, because it converted authorship from a description of contribution into an acceptance of responsibility.
A note on dates is necessary. The ICMJE’s own documents are not consistent about when the first edition appeared: the current Recommendations describe first publication in 1978 as the Uniform Requirements, while the ICMJE’s 2013 commentary on the new Recommendations describes first publication in 1979, with major revisions in 1997, 2003 and 2010 1,3. The discrepancy most probably reflects the difference between agreement of the text and its publication, but it cannot be resolved from the sources themselves, so both dates are given. A founding date cited in a thesis or a standard operating procedure (SOP) should be attributed to the specific ICMJE document from which it was taken.
The four authorship criteria and the requirements of each
The ICMJE sets four authorship criteria and requires that every author meet all four 1. Because this part of the document generates the most dispute, the function of each criterion is set out below.
Substantial contribution to conception or design, or to acquisition, analysis or interpretation of data. The operative word is “substantial”, and the list is deliberately broad: a statistician who designed and ran the analysis qualifies on this criterion as squarely as the investigator who conceived the question. Securing the funding, supervising the department, or supplying patients, samples or materials does not qualify on its own.
Drafting the work or revising it critically for important intellectual content. The operative words are “critically” and “important”. Reading a near-final draft and returning it with no substantive comment does not meet this criterion, which is why silent approval from a senior co-author is a deficiency rather than a courtesy.
Final approval of the version to be published. Every author must approve the actual final version, not a draft from three rounds earlier.
Agreement to be accountable for all aspects of the work, including ensuring that questions about the accuracy or integrity of any part are appropriately investigated and resolved. This criterion is frequently accepted without being read. It establishes that an author is answerable for parts of the paper they did not personally produce, which is precisely why authorship cannot be conferred as recognition.
The ICMJE also expects that those who meet the first criterion should be given the opportunity to meet the others; a contributor cannot legitimately be excluded from authorship by being excluded from the drafting 1.
A non-compliant author list and its correction
There are two common failures, and they tend to occur together. Honorary authorship adds someone who did not contribute — typically a department head or a sponsor executive 14. Ghost authorship omits someone who did — typically a writer or a statistician. Wislar and colleagues, in BMJ, surveyed six leading general medical journals and found the total prevalence of articles with inappropriate authorship was 21% in 2008, down from 29.1% in 1996 14. The prevalence declined only modestly and remained at roughly one paper in five, even in the journals most likely to scrutinise authorship.
The example below presents a contributorship statement that would be returned, followed by the same project reported in a form acceptable to an editor.
Prevalence of honorary or ghost authorship across six high-impact general medical journals. Source: Wislar JS, Flanagin A, Fontanarosa PB, et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ.
A contributorship statement before and after the four criteria are applied
Fails the criteria
All authors contributed to the manuscript and approved the final version. Prof. A. Lindqvist is Head of Department and secured the funding for the study. Dr R. Mehta provided the patient samples. Statistical analysis was performed by the sponsor. The manuscript was prepared with editorial assistance.
Funding and departmental oversight are listed as contributions. The ICMJE excludes both as grounds for authorship on their own.
Supplying samples is treated as authorship. Provision of materials does not qualify by itself.
The analyst is institutional, not a person. “By the sponsor” names no individual, so the contribution cannot be attributed or questioned.
The writer is invisible. “Editorial assistance” conceals a role that may have met the drafting criterion.
Criterion four is never addressed. No author has stated accountability for the whole work.
Meets them
Conception and design: K. Oyelaran, S. Fujita. Data acquisition: K. Oyelaran, R. Mehta, T. Bauer. Statistical analysis and interpretation: D. Castellanos (Northvale Therapeutics), S. Fujita. Drafting and critical revision for important intellectual content: all authors. Final approval of the submitted version: all authors. All authors agree to be accountable for all aspects of the work and for ensuring that questions about accuracy or integrity are investigated and resolved. Acknowledgements: A. Lindqvist (Head of Department, Karolinska) obtained funding and provided departmental support; medical writing support, including first-draft preparation under the authors’ direction, was provided by J. Okafor, PhD, of Meridian Scientific Communications, funded by Northvale Therapeutics. Both have given written permission to be named.
Each criterion is reported against named people, so that an editor can verify the grid rather than infer it.
The statistician is named with their employer, and qualifies on analysis and interpretation.
Funding and supervision are credited in the acknowledgements, where the ICMJE places them: credit without authorship.
The writer is named with employer and funder, and permission to be named is recorded.
Accountability for the whole work is stated explicitly, which is what criterion four asks for.
No contributor lost credit. Two contributions moved from the author list to the acknowledgements, and two previously undisclosed contributions became visible, which is the exchange the four criteria are designed to enforce. The 21% prevalence reported by Wislar and colleagues for 2008 represents the first version at scale, and it is the figure an editor has in mind when returning a contributorship form.
Contributors who are not authors, and group authorship
Every contributor who does not meet all four criteria should be listed in the acknowledgements, together with a description of their contribution. The ICMJE is explicit that this includes people whose help was substantive — writing assistance, technical editing, data collection, language help, administrative support — and that because acknowledgement can imply endorsement of the conclusions, written permission should be obtained from those named 1.
Group authorship is subject to its own rules, which are frequently overlooked. If a group name is used as the author, the journal needs to know which individuals within the group take responsibility as authors, and those individuals must each meet all four criteria; the remaining group members are listed in the acknowledgements 1. Resolving this late, after a large collaborative trial has reported, is difficult; it should be decided when the group is formed.
Where writing support is involved, the individual, their employer and the funder should be named rather than described in an abstract phrase. The reasoning, and a worked example of the difference, is on what GPP3 requires in practice.
Registration, ethics approval and data sharing requirements and their effective dates
Three ICMJE requirements have fixed triggers, and an editor can verify all three within minutes.
Trial registration. Clinical trials must be registered in a public registry at or before the time of first patient enrolment 1. Retrospective registration at submission does not satisfy the policy; because the registration date is part of the public record, the omission cannot be concealed. Steinbrook set out the rationale in the New England Journal of Medicine when the policy was introduced: registration exists so that the existence of a trial is known independently of any decision to publish it 24. Our page on trial registration under the ICMJE policy covers the mechanics.
Ethics approval. Research on human participants must conform to the Declaration of Helsinki, most recently revised in October 2024, and approval by an independent ethics committee or institutional review board must be stated in the Methods section, not merely obtained 1,3,11. A manuscript that says only “the study was conducted ethically” will be queried.
Data sharing. Since 1 July 2018, manuscripts reporting the results of clinical trials must contain a data sharing statement. Trials that began enrolling participants on or after 1 January 2019 must also include a data sharing plan in their registration. The two triggers differ: one applies to the manuscript, the other to the trial’s enrolment start date. A statement saying that data will not be shared is permitted; the absence of any statement is not.
The six conditions for acceptable secondary publication
The ICMJE prohibits duplicate publication but explicitly permits secondary publication — republication in another language, or for a different readership — under six conditions. Knowledge of the six conditions turns an uncertain question into a procedural one.
The conditions require, in substance, that both editors agree and that the secondary editor has a copy of the primary version; that an interval is respected unless both editors agree otherwise; that the secondary version is intended for a different group of readers and may be an abridgement; that it faithfully reflects the primary version’s data and interpretations; that a footnote on the title page tells readers the work was published before and gives the full primary reference; and that the title indicates it is a secondary publication of a primary report 1.
A second paper is therefore legitimate not because its content differs but because the relationship is declared where readers and indexers will see it. The same principle that separates a legitimate secondary analysis from a redundant one; it is examined, with the evidence on detection, on how duplicate publication is identified.
Where the ICMJE and GPP differ in scope
These two instruments are routinely cited together, but they serve different purposes. The ICMJE Recommendations are addressed to editors and submitters and operate at submission. GPP — published by Battisti and colleagues as GPP3 and by DeTora and colleagues as the 2022 update, both in Annals of Internal Medicine — is addressed to sponsors and their collaborators and operates across a research programme, mostly before a manuscript exists 6,10.
They agree on authorship: GPP defers to the ICMJE criteria rather than inventing its own 1,10. They agree on acknowledgement, funding disclosure and registration. They diverge on all earlier stages. GPP requires a written agreement between sponsor, authors and any agency before work begins; the ICMJE does not 10,18. GPP requires a publication plan and takes a position on which studies must be published; the ICMJE does not address a study that is never submitted. GPP addresses congress abstracts, plain-language summaries and the sponsor’s internal review process; the ICMJE addresses the manuscript in front of the editor.
In practice, questions of acceptance and declaration are answered by the ICMJE, whereas questions of how a programme should be run and who decides are answered by GPP. Neither answers the other’s question, and an organisation that has adopted only one has a visible gap. Which gap, and how to close it, is the subject of getting GPP adopted internally.
Which instrument answers which question
| Question | ICMJE Recommendations | GPP3 / GPP 2022 |
|---|---|---|
| Who may be listed as an author? | Sets the four criteria; all must be met | Defers to ICMJE, and adds sponsor-side duties |
| Who must be acknowledged? | All contributors not meeting the criteria, with permission | Same, and requires the funder of each contribution to be named |
| Must the trial be registered? | Yes — at or before first enrolment | Yes, and treats disclosure of results as independent of their direction |
| Is a written agreement needed before work starts? | Not addressed | Required, covering data control and publication veto |
| Must a completed study be published at all? | Not addressed — an unsubmitted paper is invisible to an editor | Takes a position on studies that should be published |
| Do congress abstracts and plain-language summaries count? | Only as prior publication to be declared | Treated as part of the same disclosure obligation |
| Who enforces it? | Journals, at submission | The sponsor’s own SOPs, contracts and audit |
Compiled from the ICMJE Recommendations, GPP3 (Battisti et al., Annals of Internal Medicine) and the GPP 2022 update (DeTora et al., Annals of Internal Medicine). “Not addressed” means the instrument is silent, not that it permits the practice.
Limitations of the ICMJE Recommendations
Three limitations merit attention because the document is often assumed to address them.
It does not adjudicate disputes. If co-authors disagree about the author list, the ICMJE provides criteria but no procedure; the Recommendations direct such disputes to the institutions involved, and COPE’s Core Practices are the usual source of process guidance for editors handling them 1,4.
It does not set reporting content. The ICMJE expects adherence to the relevant reporting guideline but does not contain one: CONSORT for parallel-group randomised trials, from Schulz and colleagues; PRISMA for systematic reviews, from Moher and colleagues; STROBE for observational studies, from von Elm and colleagues; CARE for case reports, from Gagnier and colleagues 12,16,20. See reporting guidelines by study type.
Finally, it cannot regulate what it cannot observe. An unregistered trial is detectable; a trial that was registered, completed and never written up is not detectable by any editor. This failure lies entirely outside the scope of the instrument, which is the strongest practical argument for reading it alongside GPP rather than in place of it.
Key points
Key points
The ICMJE Recommendations are a submission instrument. They specify who may be named as an author — all four criteria, every author, with no exceptions for funding or supervision — what must be registered and declared, and the six conditions under which a secondary publication is legitimate rather than duplicate. They are silent on the governance of a research programme before a manuscript exists, which is the territory occupied by GPP. The ICMJE Recommendations govern the acceptance of a paper; GPP governs the defensible conduct of a programme. An organisation that relies on only one of them will usually be able to identify a gap once the two are compared.
Application to your study
Application to your study
- Construct the contributorship grid before drafting the author list. The grid comprises four columns, one row per person, and a yes or no in each cell. The author list is derived from the grid rather than preceding it.
- Move any contributor with a blank cell to the acknowledgements and obtain their written permission. Seniority does not constitute a fifth criterion.
- Verify the registration date as well as the registration number. If registration postdates first enrolment, this should be disclosed and explained in the cover letter rather than left for the editor to discover.
- Report ethics approval explicitly in the Methods section. The committee and the approval reference should be named; “ethical standards were followed” is not the required statement.
- Add the data sharing statement if this is a trial report. Required since 1 July 2018; a statement that data will not be shared is acceptable, an absent statement is not.
- If the trial began enrolling on or after 1 January 2019, check the registration record as well. The data sharing plan belongs there as well as in the manuscript.
- For any second paper from the same dataset, draft the cross-reference before the abstract. The title should indicate the relationship, and a title-page footnote should give the full primary reference.
- Decide group-authorship membership when the group forms. Named individuals must each meet all four criteria; all other members are acknowledged.
Frequently asked questions
Yes. Every author must meet all four criteria. First, a substantial contribution to conception or design, or to acquisition, analysis or interpretation of data. Second, drafting the work or revising it critically for important intellectual content. Third, final approval of the version to be published. Fourth, agreement to be accountable for all aspects of the work, including ensuring that questions about accuracy or integrity are investigated and resolved. Acquiring funding, general supervision of a research group, and provision of materials or patients do not on their own qualify a contributor for authorship. Contributors who meet the first criterion should be given the opportunity to meet the others.
No. The ICMJE is a small working group of medical journal editors together with the US National Library of Medicine. It issues recommendations and maintains a list of journals that have stated they follow them, but it does not accredit, audit or certify journals, and it has no enforcement mechanism of its own. When a journal says it adheres to the ICMJE Recommendations, that is the journal’s own undertaking, and the enforcement happens through that journal’s editorial process. Any service claiming to offer ICMJE accreditation is misrepresenting what the committee is.
The sources differ slightly, and authors should note which one they cite. The current Recommendations describe first publication in 1978, as the Uniform Requirements for Manuscripts Submitted to Biomedical Journals. The ICMJE’s own 2013 commentary on the new Recommendations describes first publication in 1979, with major revisions in 1997, 2003 and 2010, and the renaming to Recommendations in 2013. The discrepancy is most likely the difference between the text being agreed and its appearing in print. It cannot be resolved from the documents, so the specific ICMJE source of the date should be cited.
The ICMJE permits secondary publication — in another language, or for a different readership — under six conditions. Both editors must agree and the secondary editor must have the primary version; an interval should be respected unless both editors agree otherwise; the secondary version must target a different readership and may be abridged; it must faithfully reflect the primary data and interpretations; a title-page footnote must tell readers the work was published before and give the full primary reference; and the title should indicate it is a secondary publication. The content need not differ. The relationship must be declared.
There are two separate triggers. Since 1 July 2018, manuscripts reporting clinical trial results must contain a data sharing statement — and a statement that data will not be shared is permitted, provided it is made. Separately, trials that began enrolling participants on or after 1 January 2019 must include a data sharing plan in their trial registration, not only in the manuscript. Authors often satisfy the first and overlook the second, because the second requires editing the registry record rather than the paper. Both should be checked if enrolment began in 2019 or later.
They differ in scope and audience. The ICMJE Recommendations are addressed to editors and submitters and operate at the point of submission: authorship, disclosure, registration, what a journal may publish. GPP — GPP3 from Battisti and colleagues, and the 2022 update from DeTora and colleagues, both in Annals of Internal Medicine — is addressed to sponsors and operates across a programme, mostly before a manuscript exists: written agreements, data control, publication planning, and an obligation to publish studies that should be published. GPP defers to the ICMJE on authorship. The ICMJE says nothing about the upstream governance GPP exists to specify.
It is sufficiently common that editors anticipate it. Wislar and colleagues, in BMJ, surveyed six leading general medical journals and found the total prevalence of articles with inappropriate authorship was 21% in 2008, down from 29.1% in 1996. That is roughly one article in five in journals with explicit authorship policies and active editorial scrutiny, so the figure in less closely policed venues is unlikely to be lower. The two failures tend to occur together: the honorary author who did not contribute, and the writer or analyst who did and was not named.
No. The requirement is registration in a public registry at or before the time of first patient enrolment, and the registration date is part of the public record, so an editor can see it. Registering a completed trial shortly before submission does not meet the policy. If a trial was registered late, the appropriate course is to disclose the fact and the reason in the cover letter and in the manuscript, accepting that some journals will decline the submission on that basis. Steinbrook’s account in the New England Journal of Medicine explains the rationale: registration exists so that a trial’s existence is known whether or not it is published.
References
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Text recycling guidelines. COPE. 2013. read 9 October 2026. par.nsf.gov
- International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
- International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
- DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
- Foltynek T, Meuschke N, Gipp B. Academic plagiarism detection: a systematic literature review. ACM Computing Surveys. 2019;52(6):1-42. doi:10.1145/3345317 read 9 October 2026. doi.org/10.1145/3345317
- Riley DS, Barber MS, Kienle GS, Aronson JK, von Schoen-Angerer T, Tugwell P, et al. CARE guidelines for case reports: explanation and elaboration document. Journal of Clinical Epidemiology. 2017;89:218-235. read 9 October 2026. community.the-hospitalist.org
- Roig M; US Office of Research Integrity. Avoiding plagiarism, self-plagiarism, and other questionable writing practices: a guide to ethical writing. US Office of Research Integrity. 2015. read 9 October 2026. equator-network.org
- Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
- World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310:2191-2194. doi:10.1001/jama.2013.281053 read 9 October 2026. doi.org/10.1001/jama.2013.281053
- Gagnier JJ, Kienle G, Altman DG, Moher D, Sox H, Riley D. The CARE guidelines: consensus-based clinical case reporting guideline development. Journal of Medical Case Reports. 2013;7(1):223. doi:10.1186/1752-1947-7-223 read 9 October 2026. doi.org/10.1186/1752-1947-7-223
- Fang FC, Steen RG, Casadevall A. Misconduct accounts for the majority of retracted scientific publications. Proceedings of the National Academy of Sciences of the USA. 2012;109(42):17028-17033. doi:10.1073/pnas.1212247109 read 9 October 2026. doi.org/10.1073/pnas.1212247109
- Wislar JS, Flanagin A, Fontanarosa PB, et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011;343:d6128. doi:10.1136/bmj.d6128 read 9 October 2026. doi.org/10.1136/bmj.d6128
- Das N, Panjabi M. Plagiarism: why is it such a big issue for medical writers? Perspectives in Clinical Research. 2011;2(2):67-71. doi:10.4103/2229-3485.80370 read 9 October 2026. doi.org/10.4103/2229-3485.80370
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
- Zhang H. CrossCheck: an effective tool for detecting plagiarism. Learned Publishing. 2010;23:9-14. read 9 October 2026. pmc.ncbi.nlm.nih.gov
- Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
- Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372. read 9 October 2026. equator-network.org
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
- Alfonso F, Bermejo J, Segovia J. Duplicate or redundant publication: can we afford it? Revista Espanola de Cardiologia. 2005;58(5):601-604. doi:10.1016/S1885-5857(06)60739-1 read 9 October 2026. doi.org/10.1016/S1885-5857(06)60739-1
- von Elm E, Poglia G, Walder B, Tramer MR. Different patterns of duplicate publication: an analysis of articles used in systematic reviews. JAMA. 2004;291(8):974-980. doi:10.1001/jama.291.8.974 read 9 October 2026. doi.org/10.1001/jama.291.8.974
- DeAngelis CD. Duplicate publication, multiple problems. JAMA. 2004;292:1745-1746. doi:10.1001/jama.292.14.1745 read 9 October 2026. doi.org/10.1001/jama.292.14.1745
- Steinbrook R. Public registration of clinical trials. New England Journal of Medicine. 2004;351:315-317. doi:10.1056/NEJMp048191 read 9 October 2026. doi.org/10.1056/NEJMp048191
- Yank V, Barnes D. Consensus and contention regarding redundant publications in clinical research: cross-sectional survey of editors and authors. Journal of Medical Ethics. 2003;29:109-114. read 9 October 2026. revespcardiol.org
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
- Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, et al. Sponsorship, authorship, and accountability. Annals of Internal Medicine. 2001;135:463-466. read 9 October 2026. ismpp.org
- Rennie D, Flanagin A, Yank V. The contributions of authors. JAMA. 2000;284:89-91. read 9 October 2026. ismpp.org
- Kassirer JP, Angell M. Redundant publication: a reminder. New England Journal of Medicine. 1995;333:449-450. doi:10.1056/NEJM199508173330709 read 9 October 2026. doi.org/10.1056/NEJM199508173330709
- Angell M, Relman AS. Redundant publication. New England Journal of Medicine. 1989;320:1212-1214. doi:10.1056/NEJM198905043201812 read 9 October 2026. doi.org/10.1056/NEJM198905043201812
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). The ICMJE Recommendations: Scope, Requirements and Limitations of the Instrument. Pubrica. https://pubrica.com/academy/publication-ethics/use-of-icmje-urm-for-ethical-guidance/
Pubrica Academy. “The ICMJE Recommendations: Scope, Requirements and Limitations of the Instrument.” Pubrica, 9 Oct. 2026, pubrica.com/academy/publication-ethics/use-of-icmje-urm-for-ethical-guidance/.
Pubrica Academy (2026) The ICMJE Recommendations: Scope, Requirements and Limitations of the Instrument. Pubrica. Available at: https://pubrica.com/academy/publication-ethics/use-of-icmje-urm-for-ethical-guidance/ (Accessed: 15 October 2026).
Pubrica Academy. “The ICMJE Recommendations: Scope, Requirements and Limitations of the Instrument.” Pubrica. October 9, 2026. https://pubrica.com/academy/publication-ethics/use-of-icmje-urm-for-ethical-guidance/
Pubrica Academy, ‘The ICMJE Recommendations: Scope, Requirements and Limitations of the Instrument’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/publication-ethics/use-of-icmje-urm-for-ethical-guidance/> accessed 15 October 2026.
Pubrica Academy. The ICMJE Recommendations: Scope, Requirements and Limitations of the Instrument. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/publication-ethics/use-of-icmje-urm-for-ethical-guidance/
Pubrica Academy, “The ICMJE Recommendations: Scope, Requirements and Limitations of the Instrument,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/publication-ethics/use-of-icmje-urm-for-ethical-guidance/
@misc{use_of_icmje_urm_for_ethical_guidance_2026,
author = {{Pubrica Academy}},
title = {The ICMJE Recommendations: Scope, Requirements and Limitations of the Instrument},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/publication-ethics/use-of-icmje-urm-for-ethical-guidance/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
ICMJE submission self-check
This checklist should be completed before any files are uploaded. An editor can verify every item in under five minutes, so an error in any one of them is a ready ground for rejection. Each item should be completed from the records rather than checked from memory.
ICMJE SUBMISSION SELF-CHECK
Manuscript: ______________________ Target journal: ______________________
Journal states it follows the ICMJE Recommendations: [ ] yes [ ] no [ ] unclear
A. AUTHORSHIP GRID (all four criteria, every author)
Name | substantial contribution | drafting or critical revision | final approval | accountable for whole work
1. ____________ | __ | __ | __ | __
2. ____________ | __ | __ | __ | __
3. ____________ | __ | __ | __ | __
4. ____________ | __ | __ | __ | __
[ ] Nobody on the list has a blank cell
[ ] Nobody is listed for funding, supervision or supply of materials alone
[ ] Everyone who met criterion 1 was given the chance to meet 2, 3 and 4
[ ] Corresponding author identified, with responsibility for communication
B. ACKNOWLEDGEMENTS
Each name below has role stated, funder named, and written permission on file:
____________ role __________________ funded by __________ permission [ ]
____________ role __________________ funded by __________ permission [ ]
[ ] Medical writer named with degree and employer, not "editorial assistance"
[ ] Group-authorship members who are not authors listed here
C. DECLARATIONS
[ ] Funding source stated
[ ] Sponsor's role described (design / conduct / analysis / decision to publish)
[ ] Conflict-of-interest disclosure completed for every author
D. ETHICS
[ ] Methods section names the ethics committee or IRB and the approval reference
Committee: ______________________ Reference: ______________
[ ] Conformity with the Declaration of Helsinki (October 2024 revision) stated
[ ] Consent arrangements described; for case reports, patient consent obtained
E. REGISTRATION (interventional studies)
Registry: ____________ Number: ____________
Registration date: ____________ First enrolment date: ____________
[ ] Registration is at or before first enrolment
[ ] If not, the discrepancy is disclosed in the cover letter and manuscript
F. DATA SHARING
[ ] Data sharing statement included (required for trial reports from 1 Jul 2018)
[ ] If enrolment began on or after 1 Jan 2019: data sharing plan is in the
REGISTRY RECORD as well as the manuscript
G. PRIOR AND SECONDARY PUBLICATION
[ ] Congress abstracts and preprints from these data declared to the editor
[ ] If this is a secondary publication: both editors informed; primary version
supplied; title indicates secondary publication; title-page footnote gives
the full primary reference; data and interpretations faithfully reflected
H. REPORTING GUIDELINE
Guideline for this design: ______________________
[ ] Completed checklist attached if the journal asks for one Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica develops the contributorship grid with the author group before the draft exists, when authorship disputes are still readily resolved, and drafts the acknowledgement, ethics, registration and data-sharing statements in the form editors expect. Where a registration date or a prior congress abstract creates a difficulty, the team identifies it and assists in disclosing it rather than leaving it unaddressed.